CJC-1295 DAC vs No DAC: Which Variant for Research?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary to release growth hormone. It exists in two variants: with DAC (Drug Affinity Complex) and without DAC (also called Modified GRF 1-29 or Mod GRF). The DAC modification is a lysine-linked maleimidopropionic acid group that binds to serum albumin, dramatically extending the half-life from 30 minutes to 6-8 days. This single modification fundamentally changes the pharmacokinetics, dosing schedule, and GH release pattern in test subjects. For research purposes only.

Mechanism: The DAC modification binds to albumin in the bloodstream, creating a depot effect that maintains elevated GHRH signalling for 6-8 days. This produces a sustained, relatively constant elevation of growth hormone levels rather than discrete pulses. Dosage: 1-2 mg once or twice per week Vial sizes: 2mg, 5mg Reconstitution: 2mL BAC water (5mg vial = 2.5mg/mL, so 2mg dose = 80 units) Half-life: 6-8 days GH pattern: Sustained elevation (less pulsatile) Best for: Protocols requiring consistent GH levels, less frequent injection schedules, or research into sustained GHRH receptor activation in test subjects.

Mechanism: Without the DAC modification, CJC-1295 has a short half-life of approximately 30 minutes. Each injection creates a sharp, discrete pulse of GH release that mimics the body's natural pulsatile secretion pattern. This is considered more physiological. Dosage: 100-300 mcg per injection, 1-3 times daily Vial sizes: 5mg, 10mg Reconstitution: 2mL BAC water (5mg vial = 2.5mg/mL = 25 mcg/unit, so 100mcg = 4 units) Half-life: ~30 minutes GH pattern: Sharp pulses (mimics natural rhythm) Best for: Stacking with GHRP/Ipamorelin, protocols requiring natural GH pulsatility, or research into acute GHRH receptor activation in test subjects.

Half-life: DAC = 6-8 days | No DAC = ~30 minutes Injection frequency: DAC = 1-2x per week | No DAC = 1-3x daily GH release pattern: DAC = Sustained/constant | No DAC = Pulsatile/natural Dose per injection: DAC = 1-2 mg | No DAC = 100-300 mcg Stacking with Ipamorelin: DAC = Less common | No DAC = Standard practice Convenience: DAC = Higher (fewer injections) | No DAC = Lower (daily dosing) Physiological mimicry: DAC = Less natural | No DAC = More natural Cost per week: DAC = Similar | No DAC = Similar Receptor desensitisation risk: DAC = Higher (constant stimulation) | No DAC = Lower (intermittent)

Choose CJC-1295 with DAC when: The protocol requires minimal injection frequency, sustained GH elevation is the research objective, or compliance with daily injections is a concern for the study design. Choose CJC-1295 without DAC when: The protocol aims to preserve natural pulsatile GH release, stacking with Ipamorelin or GHRP peptides (the most common use case), or the research investigates acute GHRH receptor activation and recovery in test subjects. The No DAC variant is far more commonly used in research protocols because it pairs synergistically with GH secretagogues (Ipamorelin, GHRP-2, GHRP-6) to create amplified GH pulses. The DAC variant is preferred when injection frequency must be minimised. For research purposes only.